NECLIFE.NS Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: January 10, 2026
Report Source: 2026 2nd Quarter Report
Nectar Lifesciences Ltd. Stock Analysis NECLIFE.NS
Nectar Lifesciences Ltd. is a holding company, which engages in the manufacture and distribution of pharmaceutical products. The firm's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The firm is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The firm offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Read More Nectar Lifesciences Ltd (NECLIFE.NS) Chart
Key Statistics of Nectar Lifesciences Ltd (NECLIFE.NS)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
₹12.75Volume
91.66KP/E Ratio (TTM)
-52 Week Range
Market Cap
2.73BAvg. Volume
441.18KDividend Yield
-Financial Metrics & Statements of Nectar Lifesciences Ltd (NECLIFE.NS)
FAQ's for Nectar Lifesciences Ltd (NECLIFE.NS)
- According to Musaffa’s Shariah screening methodology, Nectar Lifesciences Ltd (NECLIFE.NS) is currently classified as NOT HALAL as of January 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.